Cytochrome P450 2C24: expression, tissue distribution, high-throughput assay, and pharmacological inhibition

Capdevila, 1992, Cytochrome P450 and the arachidonate cascade, FASEB J, 6, 731, 10.1096/fasebj.6.2.1537463 Capdevila, 1991, Cytochrome P450 arachidonic acid epoxygenase: stereochemical characterization of epoxyeicosatrienoic acids, Methods Enzymol, 206, 441, 10.1016/0076-6879(91)06113-H Kroetz, 2002, Cytochrome P450 pathways of arachidonic acid metabolism, Curr Opin Lipidol, 13, 273, 10.1097/00041433-200206000-00007 Pfister, 2010, Vascular pharmacology of epoxyeicosatrienoic acids, Adv Pharmacol, 60, 27, 10.1016/B978-0-12-385061-4.00002-7 Sudhahar, 2010, Epoxyeicosatrienoic acid analogs and vascular function, Curr Med Chem, 17, 1181, 10.2174/092986710790827843 Iliff, 2009, Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels, Am J Physiol Heart Circ Physiol, 296, H1352, 10.1152/ajpheart.00950.2008 Heinricher, 2010, Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor, J Neurophysiol, 104, 3222, 10.1152/jn.00681.2010 Conroy, 2010, Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling, Nat Neurosci, 13, 284, 10.1038/nn.2497 Terashvili, 2008, Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray, J Pharmacol Exp Ther, 326, 614, 10.1124/jpet.108.136739 Capdevila, 2000, Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase, J Lipid Res, 41, 163, 10.1016/S0022-2275(20)32049-6 Zeldin, 2001, Epoxygenase pathways of arachidonic acid metabolism, J Biol Chem, 276, 36059, 10.1074/jbc.R100030200 Imig, 2000, Epoxygenase metabolites. Epithelial and vascular actions, Mol Biotechnol, 16, 233, 10.1385/MB:16:3:233 Thompson, 2000, Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid, J Pharmacol Exp Ther, 294, 1120 Oleksiak, 2000, Identification, functional characterization, and regulation of a new cytochrome P450 subfamily, the CYP2Ns, J Biol Chem, 275, 2312, 10.1074/jbc.275.4.2312 Stark, 2008, Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide, FEBS J, 275, 3706, 10.1111/j.1742-4658.2008.06518.x Iliff, 2009, Epoxyeicosanoid signaling in CNS function and disease, Prostaglandins Other Lipid Mediat, 91, 68, 10.1016/j.prostaglandins.2009.06.004 Martignoni, 2006, Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction, Expert Opin Drug Metab Toxicol, 2, 875, 10.1517/17425255.2.6.875 Zaphiropoulos, 1991, cDNA cloning and regulation of a novel rat cytochrome P450 of the 2C gene subfamily (P450IIC24), Biochem Biophys Res Commun, 180, 645, 10.1016/S0006-291X(05)81114-3 Zaphiropoulos, 1993, Differential expression of cytochrome P450 2C24 transcripts in rat kidney and prostate: evidence indicative of alternative and possibly trans splicing events, Biochem Biophys Res Commun, 192, 778, 10.1006/bbrc.1993.1482 Holla, 1999, The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading, J Clin Invest, 104, 751, 10.1172/JCI7013 Hough, 2007, CC12, a high-affinity ligand for [3H] cimetidine binding, is an improgan antagonist, Neuropharmacology, 52, 1244, 10.1016/j.neuropharm.2007.01.004 Ding, 1988, Purification and characterization of two unique forms of cytochrome P-450 from rabbit nasal microsomes, Biochemistry, 27, 8330, 10.1021/bi00422a007 Trogadis, 1995, Dopamine D1 receptor distribution in Sf9 cells imaged by confocal microscopy: a quantitative evaluation, J Histochem Cytochem, 43, 497, 10.1177/43.5.7730588 Crespi, 1997, Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450, Anal Biochem, 248, 188, 10.1006/abio.1997.2145 VanAlstine, 2011, Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome P450s, Drug Metab Dispos, 39, 1221, 10.1124/dmd.110.037424 Daikh, 1994, Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9, J Pharmacol Exp Ther, 271, 1427 Bylund, 1998, Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS, Anal Biochem, 265, 55, 10.1006/abio.1998.2897 Zeldin, 1995, Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform, Arch Biochem Biophys, 322, 76, 10.1006/abbi.1995.1438 Goldstein, 1994, Biochemistry and molecular biology of the human CYP2C subfamily, Pharmacogenetics, 4, 285, 10.1097/00008571-199412000-00001 Rahman, 1994, Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8, Cancer Res, 54, 5543 Andersson, 1992, Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects, Pharmacogenetics, 2, 25, 10.1097/00008571-199202000-00005 Hedlund, 2001, Cytochrome P450 in the brain; a review, Curr Drug Metab, 2, 245, 10.2174/1389200013338513 Doray, 2001, N-terminal deletions and His-tag fusions dramatically affect expression of cytochrome p450 2C2 in bacteria, Arch Biochem Biophys, 393, 143, 10.1006/abbi.2001.2473 Czerniak, 2001, Gender-based differences in pharmacokinetics in laboratory animal models, Int J Toxicol, 20, 161, 10.1080/109158101317097746 Trubetskoy, 2005, Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes, J Biomol Screen, 10, 56, 10.1177/1087057104269731 Hough, 2011, Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic, Pain, 152, 878, 10.1016/j.pain.2011.01.001 Stadel, 2008, High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain, Drug Metab Dispos, 36, 614, 10.1124/dmd.107.017889 Wang, 1998, Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors, J Pharmacol Exp Ther, 284, 966 Brand-Schieber, 2000, Selective inhibition of arachidonic acid epoxidation in vivo, J Physiol Pharmacol, 51, 655 Nguyen, 1999, Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors, Am J Physiol, 276, R1691 Zou, 1994, Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats, J Pharmacol Exp Ther, 268, 474 Chen, 2009, 20-125Iodo-14,15-epoxyeicosa-5(Z)-enoic acid: a high-affinity radioligand used to characterize the epoxyeicosatrienoic acid antagonist binding site, J Pharmacol Exp Ther, 331, 1137, 10.1124/jpet.109.157818 Hough LB, Nalwalk JW, Barnes WG, Leurs R, Menge WM, Timmerman H. A third legacy for burimamide: discovery and characterization of improgan and a new class of non-opioid analgesics derived from histamine antagonists. Watanabe T, Timmerman H, Yanai K, editors. Excerpta medica international congress series 1224. Proceedings of the international Sendai histamine symposium: histamine research in the new millenium; 2000 November; Sendai, Japan. Amsterdam: Elsevier; 2001. p. 237–42. Zhang, 2002, Inhibition of cytochromes P450 by antifungal imidazole derivatives, Drug Metab Dispos, 30, 314, 10.1124/dmd.30.3.314 Winter, 2005, Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism, Drug Metab Dispos, 33, 969, 10.1124/dmd.104.002998 Kunze, 1996, Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies, Drug Metab Dispos, 24, 414 Walsky, 2005, Examination of 209 drugs for inhibition of cytochrome P450 2C8, J Clin Pharmacol, 45, 68, 10.1177/0091270004270642 Zou, 2002, Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity, Life Sci, 71, 1579, 10.1016/S0024-3205(02)01913-6 Ko, 2000, In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6, Br J Clin Pharmacol, 49, 343, 10.1046/j.1365-2125.2000.00175.x Usmani, 2004, In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily, Drug Metab Dispos, 32, 333, 10.1124/dmd.32.3.333 Marques-Soares, 2003, Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes, Biochemistry, 42, 6363, 10.1021/bi027391+